Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Diffusion Pharmaceuticals stock

Own Diffusion Pharmaceuticals stock in just a few minutes.


Fact checked

Diffusion Pharmaceuticals Inc is a biotechnology business based in the US. Diffusion Pharmaceuticals shares (DFFN) are listed on the NASDAQ and all prices are listed in US Dollars. Diffusion Pharmaceuticals employs 10 staff and has a market cap (total outstanding shares value) of USD$54.4 million.

How to buy shares in Diffusion Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Diffusion Pharmaceuticals. Find the stock by name or ticker symbol: DFFN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Diffusion Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Diffusion Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Diffusion Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Diffusion Pharmaceuticals share price

Use our graph to track the performance of DFFN stocks over time.

Diffusion Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
52-week range USD$0.211 - USD$1.6
50-day moving average USD$0.8669
200-day moving average USD$0.9153
Wall St. target price USD$2.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.973

Buy Diffusion Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Diffusion Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Diffusion Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -28.74%
Return on equity TTM -49.91%
Profit margin 0%
Book value $0.514
Market capitalisation USD$54.4 million

TTM: trailing 12 months

Shorting Diffusion Pharmaceuticals shares

There are currently 853,648 Diffusion Pharmaceuticals shares held short by investors – that's known as Diffusion Pharmaceuticals's "short interest". This figure is 25.8% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Diffusion Pharmaceuticals shares can be evaluated.

Diffusion Pharmaceuticals's "short interest ratio" (SIR)

Diffusion Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Diffusion Pharmaceuticals shares currently shorted divided by the average quantity of Diffusion Pharmaceuticals shares traded daily (recently around 1.4 million). Diffusion Pharmaceuticals's SIR currently stands at 0.62. In other words for every 100,000 Diffusion Pharmaceuticals shares traded daily on the market, roughly 620 shares are currently held short.

However Diffusion Pharmaceuticals's short interest can also be evaluated against the total number of Diffusion Pharmaceuticals shares, or, against the total number of tradable Diffusion Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Diffusion Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Diffusion Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0134% of the tradable shares (for every 100,000 tradable Diffusion Pharmaceuticals shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Diffusion Pharmaceuticals.

Find out more about how you can short Diffusion Pharmaceuticals stock.

Diffusion Pharmaceuticals share dividends

We're not expecting Diffusion Pharmaceuticals to pay a dividend over the next 12 months.

Have Diffusion Pharmaceuticals's shares ever split?

Diffusion Pharmaceuticals's shares were split on a 1:15 basis on 14 December 2018. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Diffusion Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Diffusion Pharmaceuticals shares which in turn could have impacted Diffusion Pharmaceuticals's share price.

Diffusion Pharmaceuticals share price volatility

Over the last 12 months, Diffusion Pharmaceuticals's shares have ranged in value from as little as $0.211 up to $1.6. A popular way to gauge a stock's volatility is its "beta".

DFFN.US volatility(beta: 2.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Diffusion Pharmaceuticals's is 2.0532. This would suggest that Diffusion Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Diffusion Pharmaceuticals overview

Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site